Drug Trial Radar · NCT02502968
BL-8040 Addition to Consolidation Therapy in AML Patients
Last checked: Nov 19, 2026Latest source record: Sep 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
194
Planned (sponsor's estimate)
Start
Sep 2015
Primary completion
Jul 2018
Sponsor
- Lead sponsor
- Dr. Petra TschanterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BioLineRx, Ltd.
- First posted
- Jul 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the addition of BL-8040 to the standard consolidation therapy with cytarabine in the treatment of acute myeloid leukemia (AML) in adults. Half of participants will receive BL-8040 and cytarabine in combination, while the other half will receive placebo and cytarabine.
Conditions
- Acute Myeloid Leukemia
Interventions
CytarabineDrug
BL-8040Drug
Placebo (for BL-8040)Drug
Powder for solution for injection manufactured to mimic BL-8040
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse Free Survival timeTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Univeritätsklinikum Halle, Klinik Innere Medizin 4
Halle, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.